Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Figure S1B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1380.0,1.0,G75V + T76I,75,G75V + T76I,1,=,702.0,1.0,=,2.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Figure S1B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1963.0,1.0,G75V + T76I,75,G75V + T76I,1,=,1955.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Figure S1B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1010.0,1.0,G75V + T76I,75,G75V + T76I,1,=,1107.0,1.0,=,0.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Figure S1B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1305.0,1.0,G75V + T76I,75,G75V + T76I,1,=,1257.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Figure S1B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1879.0,1.0,G75V + T76I,75,G75V + T76I,1,=,1533.0,1.0,=,1.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Figure S1B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2028.0,1.0,G75V + T76I,75,G75V + T76I,1,=,2418.0,1.0,=,0.8